59839-23-5

Usage

Uses

Used in Pharmaceutical Industry:
1,2,3,4-Tetrahydro-isoquinolin-6-ol hydrobromide is used as a chemical reagent for the preparation of androgen receptor modulators (SARMs). These compounds are designed to selectively target androgen receptors, offering potential therapeutic benefits for conditions related to muscle wasting, osteoporosis, and other disorders.
1,2,3,4-Tetrahydro-isoquinolin-6-ol hydrobromide is also used as a chemical reagent in the synthesis of steroidmimetic compounds. These molecules mimic the structure and function of steroid hormones, which can be utilized in the development of drugs targeting various medical conditions, including inflammation, immune disorders, and hormonal imbalances.
Furthermore, 1,2,3,4-Tetrahydro-isoquinolin-6-ol hydrobromide is employed in the preparation of chimeric microtubule disruptors. These compounds are designed to interfere with the normal function of microtubules, which are essential components of the cellular cytoskeleton. By disrupting microtubule function, these chimeric compounds can inhibit cell division and proliferation, making them potential candidates for cancer therapy.

InChI:InChI=1/C9H11NO.BrH/c11-9-2-1-8-6-10-4-3-7(8)5-9;/h1-2,5,10-11H,3-4,6H2;1H

Upstream product

• 42923-77-3 6-methoxy-1,2,3,4-tetrahydro-isoquinoline 
• 22246-12-4 6-methoxy-1,2,3,4-tetrahydro-1-oxoisoquinoline 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 860436-57-3 tert-butyl 6-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 57196-62-0 6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 591-31-1 3-methoxy-benzaldehyde 
• 3179-09-7 1-methoxy-3-(2-nitrovinyl)benzene 
• 942150-85-8 bis(6-methoxy-N-1,2,3,4-tetrahydroisoquinolinyl)methane 
• 33543-63-4 ethyl-N-<2-(3-methoxyphenyl)ethyl>-carbamate 
• 541-41-3 chloroformic acid ethyl ester 
• 110192-21-7 N-(methoxycarbonyl)-2-(3'-methoxyphenyl)ethylamine 

Downstream Products

• 158984-83-9 N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 166398-33-0 tert-butyl 6-cyano-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 158984-84-0 6-trifluoromethanesulfonyloxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 800373-89-1 (6-hydroxy-3,4-dihydro-1H-isoquinolin-2-yl)-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-methanone 
• 94085-74-2 6-hydroxy-2-(3-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 1064205-99-7 2-(2-methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol 
• 1064199-27-4 2-(3-acetylbenzyl)-7-methoxy-6-sulfamoyloxy-1,2,3,4-tetrahydroisoquinoline 
• 1064200-01-6 2-(3,5-dimethoxybenzoyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 185057-06-1 6-Hydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester 
• 893566-72-8 6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 1429253-97-3 C₂₈H₂₆N₄O₂ 
• 1429254-04-5 C₂₄H₂₅N₃O₃ 
• 630407-52-2 6-ethoxy-1,2,3,4-tetrahydro-isoquinoline 
• 252061-94-2 6-benzyloxy-1,2,3,4-tetrahydro-isoquinoline 

Relevant academic research and scientific papers

MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION

Disclosed are a class of new monocyclic β-lactam compounds, an isomer thereof or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compounds, and the use of same in preparing drugs for treating diseases associated

CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE

The present invention provides novel compounds having the general formula (I) wherein R1 to R6, and m are as described herein, compositions including the compounds and methods of using the compounds.

SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS

The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related di

Design and synthesis of novel androgen receptor antagonists via molecular modeling

Several androgen receptor (AR) antagonists are clinically prescribed to treat prostate cancer. Unfortunately, many patients become resistant to the existing AR antagonists. To overcome this, a novel AR antagonist candidate called DIMN was discovered by our research group in 2013. In order to develop compounds with improved potency, we designed novel DIMN derivatives based on a docking study and substituted carbons with heteroatom moieties. Encouraging in vitro results for compounds 1b, 1c, 1e, 3c, and 4c proved that the new design was successful. Among the newly synthesized compounds, 1e exhibited the strongest inhibitory effect on LNCaP cell growth (IC50= 0.35 μM) and also acted as a competitive AR antagonist with selectivity over the estrogen receptor (ER) and the glucocorticoid receptor (GR). A docking study of compound 1e fully supported these biological results. Compound 1e is considered to be a novel, potent and AR-specific antagonist for treating prostate cancer. Thus, our study successfully applied molecular modeling and bioisosteric replacement for hit optimization. The methods here provide a guide for future development of drug candidates through structure-based drug discovery and chemical modifications.

Tetrahydroisoquinolinone-based steroidomimetic and chimeric microtubule disruptors

A structure-activity relationship (SAR) translation strategy was used for the discovery of tetrahydroisoquinoline (THIQ)-based steroidomimetic and chimeric microtubule disruptors based upon a steroidal starting point. A steroid A,B-ring-mimicking THIQ core was connected to methoxyaryl D-ring ring mimics through methylene, carbonyl and sulfonyl linkers to afford a number of steroidomimetic hits (e.g., 7-methoxy-2-(3- methoxybenzyl)-6-sulfamoyloxy-1,2,3, 4-tetrahydroisoquinoline (20 c) GI50=2.1 μM). Optimisation and control experiments demonstrate the complementary SAR of this series and the steroid derivatives that inspired its design. Linkage of the THIQ-based A,B-mimic with the trimethoxyaryl motif prevalent in colchicine site binding microtubule disruptors delivered a series of chimeric molecules whose activity (GI50=40 nM) surpasses that of the parent steroid derivatives. Validation of this strategy was obtained from the excellent oral activity of 7-methoxy-6-sulfamoyloxy-2-(3,4,5-trimethoxybenzyl)-1,2,3,4- tetrahydroisoquinoline (20 z) relative to a benchmark steroidal bis- sulfamate Copyright

SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS

The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particulalrly FabI inhibitors. Formula(I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage anti-bacterial agents, more particularly FabI inhibitors. The present invention also provides methods for synthesizing and administering the FabI inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer

Molecular knowledge of pure antagonism and systematic SAR study offered a direction for structural optimization of DIMN to provide nicotinamides as a novel series of AR antagonists. Nicotinamides with extended linear scaffold bearing sterically bulky alkoxy groups on isoquinoline end were synthesized for H12 displacement. AR binding affinity and molecular basis of antiandrogenic effect establish the optimized derivatives, 7au and 7bb, as promising candidates of second generation AR antagonists for advanced prostate cancer.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.